10 January 2022 - The National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination recommending Rinvoq (upadacitinib) 15 mg as a new option for treating adults with active psoriatic arthritis.

This treatment is recommended for patients who have peripheral arthritis with three or more tender joints, and three or more swollen ligaments.

Read Pharma Times article